GlassScriptPhysician profile
James H Sherman
NPI 1225165111
$10,512.16
in general payments reported to CMS, 2019-2025
45 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $980 · 2021: $1,755 · 2022: $2,258 · 2023: $1,773 · 2024: $1,890 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,634.35 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,581.21 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Ferring Pharmaceuticals INC. | $1,053.33 | 2019-2023 | Clenpiq, Rebyota |
| Daiichi Sankyo INC. | $420.53 | 2019-2025 | Injectafer |
| Janssen Biotech, INC. | $279.77 | 2019-2024 | Stelara, Tremfya, Simponi |
| Novartis Pharmaceuticals Corporation | $252.28 | 2019-2023 | |
| Novo Nordisk INC | $240.18 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $216.74 | 2024 | Arcalyst |
| Amgen INC. | $198.07 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.31 | 2021-2024 | Lifevest |
| Nestle Healthcare Nutrition INC. | $186.91 | 2020-2023 | |
| Lilly USA, LLC | $185.25 | 2022-2024 | Mounjaro, Zepbound |
| Genzyme Corporation | $165.37 | 2019-2024 | |
| Romark Laboratories, Lc | $147.99 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $147.52 | 2022-2023 | Arcalyst |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.